Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wils, J. A.
Right arrow Articles by Buyse, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wils, J. A.
Right arrow Articles by Buyse, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 9, 827-831, Copyright © 1991 by American Society of Clinical Oncology

ARTICLES

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group

JA Wils, HO Klein, DJ Wagener, H Bleiberg, H Reis, F Korsten, T Conroy, M Fickers, S Leyvraz and M Buyse
Laurentius Hospital, Roermond, The Netherlands.

In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate (MTX), fluorouracil (5-FU), and Adriamycin (doxorubicin; Farmitalia Carlo Erba, Milan, Italy) (FAMTX) or 5-FU, Adriamycin, and mitomycin (FAM). The results show a significantly superior response rate (41% v 9% [P less than .0001]), and survival (median, 42 weeks v 29 weeks [P = .004]) for FAMTX. There was a cumulative thrombocytopenia in FAM and not in FAMTX. The FAMTX protocol should be the reference treatment in future clinical trials that seek to improve the therapeutic outcome in advanced gastric cancer.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
I. Chau, A. R. Norman, D. Cunningham, J. Oates, R. Hawkins, T. Iveson, M. Nicolson, P. Harper, M. Seymour, and T. Hickish
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
Ann. Onc., May 1, 2009; 20(5): 885 - 891.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. F. Aykan and E. Idelevich
The role of UFT in advanced gastric cancer
Ann. Onc., June 1, 2008; 19(6): 1045 - 1052.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-G. Kim, S. Y. Oh, H.-C. Kwon, S. Lee, J. H. Kim, S.-H. Kim, and H.-J. Kim
A Phase II Study of Irinotecan with Bi-weekly, Low-dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFIRI) as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Jpn. J. Clin. Oncol., October 8, 2007; (2007) hym103v1.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Boku, A. Ohtsu, F. Nagashima, K. Shirao, and W. Koizumi
Relationship between Expression of Vascular Endothelial Growth Factor in Tumor Tissue from Gastric Cancers and Chemotherapy Effects: Comparison between S-1 alone and the Combination of S-1 plus CDDP
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym057v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. W. Gee and D. W. Rattner
Management of Gastroesophageal Tumors
Oncologist, February 1, 2007; 12(2): 175 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W Ichikawa and Y Sasaki
Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients
Ann. Onc., November 1, 2006; 17(11): 1665 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ohtsu, S. Yoshida, and N. Saijo
Disparities in Gastric Cancer Chemotherapy Between the East and West
J. Clin. Oncol., May 10, 2006; 24(14): 2188 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Nitti, J. Wils, J. G. Dos Santos, G. Fountzilas, P. F. Conte, C. Sava, A. Tres, R. C. Coombes, D. Crivellari, A. Marchet, et al.
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
Ann. Onc., February 1, 2006; 17(2): 262 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
F. Nagashima, N. Boku, A. Ohtsu, S. Yoshida, T. Hasebe, A. Ochiai, Y. Sakata, H. Saito, Y. Miyata, I. Hyodo, et al.
Biological Markers as a Predictor for Response and Prognosis of Unresectable Gastric Cancer Patients Treated with Irinotecan and Cisplatin
Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 714 - 719.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Lim, M. Michael, G. B. Mann, and T. Leong
Adjuvant Therapy in Gastric Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Pozzo, C. Barone, J. Szanto, E. Padi, C. Peschel, J. Bukki, V. Gorbunova, V. Valvere, J. Zaluski, M. Biakhov, et al.
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
Ann. Onc., December 1, 2004; 15(12): 1773 - 1781.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Bouche, J. L. Raoul, F. Bonnetain, M. Giovannini, P. L. Etienne, G. Lledo, D. Arsene, J. F. Paitel, V. Guerin-Meyer, E. Mitry, et al.
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
J. Clin. Oncol., November 1, 2004; 22(21): 4319 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. S. Wohrer, M. Raderer, and M. Hejna
Palliative chemotherapy for advanced gastric cancer
Ann. Onc., November 1, 2004; 15(11): 1585 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, A. Kotsakis, et al.
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
Ann. Onc., August 1, 2004; 15(8): 1204 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Assersohn, G. Brown, D. Cunningham, C. Ward, J. Oates, J. S. Waters, M. E. Hill, and A. R. Norman
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
Ann. Onc., January 1, 2004; 15(1): 64 - 69.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Cocconi, P. Carlini, A. Gamboni, S. Gasperoni, C. Rodino, S. Zironi, G. Bisagni, S. Porrozzi, F. Cognetti, F. Di Costanzo, et al.
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma
Ann. Onc., August 1, 2003; 14(8): 1258 - 1263.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. D. Roth
Chemotherapy in gastric cancer: a never ending saga
Ann. Onc., February 1, 2003; 14(2): 175 - 177.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. F. Kruijtzer, H. Boot, J. H. Beijnen, H. L. Lochs, F. X. Parnis, A. S. T. Planting, J. M. G. Pelgrims, R. Williams, R. A. A. Mathot, H. Rosing, et al.
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
Ann. Onc., February 1, 2003; 14(2): 197 - 204.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ohtsu, Y. Shimada, K. Shirao, N. Boku, I. Hyodo, H. Saito, N. Yamamichi, Y. Miyata, N. Ikeda, S. Yamamoto, et al.
Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)
J. Clin. Oncol., January 1, 2003; 21(1): 54 - 59.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Louvet, T. Andre, J.M. Tigaud, E. Gamelin, J.Y. Douillard, R. Brunet, E. Francois, J.H. Jacob, D. Levoir, A. Taamma, et al.
Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients
J. Clin. Oncol., December 1, 2002; 20(23): 4543 - 4548.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview
Oncologist, December 1, 2002; 7(6): 516 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. C. Tebbutt, A. Norman, D. Cunningham, T. Iveson, M. Seymour, T. Hickish, P. Harper, N. Maisey, K. Mochlinski, Y. Prior, et al.
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
Ann. Onc., October 1, 2002; 13(10): 1568 - 1575.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. H. Ilson
Epirubicin, Cisplatin, and Fluorouracil in Gastric and Esophageal Cancer: A Step Ahead?
J. Clin. Oncol., April 15, 2002; 20(8): 1962 - 1964.
[Full Text] [PDF]

Home page
 JCOHome page
P. Ross, M. Nicolson, D. Cunningham, J. Valle, M. Seymour, P. Harper, T. Price, H. Anderson, T. Iveson, T. Hickish, et al.
Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
J. Clin. Oncol., April 15, 2002; 20(8): 1996 - 2004.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y.-C. Lin, J.-S. Chen, C.-H. Wang, H.-M. Wang, H.-K. Chang, C.-T. Liau, T.-S. Yang, C.-C. Liaw, and H.-E. Liu
Weekly High-dose 5-Fluorouracil (5-FU), Leucovorin (LV) and Bimonthly Cisplatin in Patients with Advanced Gastric Cancer
Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 605 - 609.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. C. Tebbutt, A. Norman, M. Hill, D. Cunningham, and J. A. Ajani
Standard Chemotherapy for Gastric Carcinoma: Is It a Myth?
J. Clin. Oncol., May 15, 2001; 19(10): 2765 - 2767.
[Full Text] [PDF]

Home page
 JCOHome page
J. A. Ajani, H. Wilke, U. Vanhoefer, P. Rougier, B. Nordlinger, E. Van Cutsem, J. A. Wils, and B. Baron
Standard Chemotherapy for Gastric Carcinoma: Is It a Myth?
J. Clin. Oncol., December 1, 2000; 18(23): 4001 - 4003.
[Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke
The Treatment of Advanced Gastric Cancer: In Search of the Right Combination
J. Clin. Oncol., July 14, 2000; 18(14): 2645 - 2647.
[Full Text] [PDF]

Home page
 JCOHome page
U. Vanhoefer, P. Rougier, H. Wilke, M. P. Ducreux, A. J. Lacave, E. Van Cutsem, M. Planker, J. G. D. Santos, P. Piedbois, B. Paillot, et al.
Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group
J. Clin. Oncol., July 14, 2000; 18(14): 2648 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A L Thomas, K O'Byrne, and W P Steward
Chemotherapy for upper gastrointestinal tumours
Postgrad. Med. J., June 1, 2000; 76(896): 321 - 321.
[Abstract] [Full Text]

Home page
 JCOHome page
L. Cirera, A. Balil, E. Batiste-Alentorn, I. Tusquets, T. Cardona, A. Arcusa, L. Jolis, E. Saigi, I. Guasch, A. Badia, et al.
Randomized Clinical Trial of Adjuvant Mitomycin Plus Tegafur in Patients With Resected Stage III Gastric Cancer
J. Clin. Oncol., December 1, 1999; 17(12): 3810 - 3815.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Bamias and N. Pavlidis
Systemic Chemotherapy in Gastric Cancer: Where Do We Stand Today?
Oncologist, June 1, 1998; 3(3): 171 - 177.
[Abstract] [Full Text]

Home page
 NEJMHome page
C. S. Fuchs and R. J. Mayer
Gastric Carcinoma
N. Engl. J. Med., July 6, 1995; 333(1): 32 - 41.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1991 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online